Business
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6\n\n\n\n\n\nRegen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6\nCompany focuses on developing small molecule checkpoint inhibitors and immune suppressants\nPR Newswire\nSAN DIEGO, June 2, 2016\n\n\n\nSAN DIEGO, June 2, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6.  This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a \"checkpoint inhibitor pill.\"  Previously, the Company reported the use of gene silencing of NR2F6 leads to:\n\na) induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign and b) immune cell activation, including production of IL-18 and IL-2.\n\n\"We have gathered several well thought out chemical libraries which are most likely to give us new chemical entities that inhibit and/or activate NR2F6.  We are optimistic that this program will identify lead compounds in the near term that potentially create a new generation of immune-stimulatory anticancer drugs.  The Company believes these oral drugs will on the one hand unleash anticancer immune responses and on the other hand directly reprogram cancers rendering them less malignant,\" said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  \"This small molecule approach complements our tCellVax program whereby NR2F6-gene expression in autologous immune cells is inhibited using siRNA.  We believe that by using two independent approaches towards the same target we will be in a position to accelerate clinical implementation and diversify our product pipeline.  If we are also fortunate enough to identify an activator of NR2F6, we will be in a position to begin a program on treating auto-immune disorders such as rheumatoid arthritis, eczema, graft versus host disease and lupus.\"\n\nNR2F6 is a molecular switch known as a \"orphan nuclear receptor\", which controls genes associated with the immune response as well as genes associated with the ability o...